{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T10:25:27Z","timestamp":1793701527638,"version":"4.5.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Wu Jieping Clinical Research Projects","award":["320.6750.2020-15-3"],"award-info":[{"award-number":["320.6750.2020-15-3"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program","doi-asserted-by":"crossref","award":["2022YFC2403400"],"award-info":[{"award-number":["2022YFC2403400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Sichuan Province Clinical Key Specialty Construction Project"},{"name":"International Cooperation Projects of Science and Technology Department of Sichuan Province","award":["24GJHZ0166"],"award-info":[{"award-number":["24GJHZ0166"]}]},{"name":"the Sichuan Key Research and Development Project from Science and Technology Department of Sichuan Province","award":["2022YFQ0008"],"award-info":[{"award-number":["2022YFQ0008"]}]},{"name":"the Sichuan Key Research and Development Project from Science and Technology Department of Sichuan Province","award":["2023YFQ0055"],"award-info":[{"award-number":["2023YFQ0055"]}]},{"name":"the Sichuan Key Research and Development Project from Science and Technology Department of Sichuan Province","award":["2023YFQ0056"],"award-info":[{"award-number":["2023YFQ0056"]}]},{"name":"the Sichuan Key Research and Development Project from Science and Technology Department of Sichuan Province","award":["2023YFS0044"],"award-info":[{"award-number":["2023YFS0044"]}]},{"name":"the Sichuan Key Research and Development Project from Science and Technology Department of Sichuan Province","award":["2023YFS0488"],"award-info":[{"award-number":["2023YFS0488"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The morbidity and mortality rates of esophageal squamous cell carcinoma (ESCC) are high in China. The overall survival (OS) of patients with ESCC is related to lymph node (LN) metastasis (LNM). This study aimed to discuss the impact of metastasis in LN stations on the OS of patients with pathologic N1 (pN1) ESCC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data were obtained from the Esophageal Cancer Case Management database of Sichuan Cancer Hospital and Institute (SCCH-ECCM). Additionally, data of patients with pN1-category ESCC collected between January 2010 and December 2017 were retrospectively analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Data from 807 patients were analyzed. The median OS of the patients with one metastatic LN (group 1) was 49.8 months (95 % confidence interval [CI], 30.8\u201368.9 months), whereas the OS of those with two metastatic LNs (group 2) was only 33.3 months (<jats:italic>P<\/jats:italic> = 0.0001). Moreover, group 1 did not show a significantly longer OS than group 2.1 (patients with 2 metastatic LNs in 1 LNM station; <jats:italic>P<\/jats:italic> = 0.5736), but did show a significantly longer OS than group 2.2 (patients with 2 metastatic LNs in 2 LNM stations; <jats:italic>P<\/jats:italic> &lt; 0.0001). After propensity score-matching, the 5-year survival rate for group 1 was 28 %, whereas that for group 2 was 14 % (<jats:italic>P<\/jats:italic> = 0.0027).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The OS for the patients with one metastatic LN in one LNM was not significantly longer than for the patients with two metastatic LNs in one LNM station. Patients with one LNM station had a significantly longer OS than those with two LNM stations. Thus, the number of LNM stations is a significant determinant of OS in pN1 ESCC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-024-15019-z","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T16:03:14Z","timestamp":1708358594000},"page":"3794-3802","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Impact of Metastatic Lymph Nodes on Survival of Patients with pN1-Category Esophageal Squamous Cell Carcinoma: A Long-Term Survival Analysis"],"prefix":"10.1245","volume":"31","author":[{"given":"Kexun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunyi","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changding","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simiao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongtao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunchao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5897-0419","authenticated-orcid":false,"given":"Xuefeng","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"key":"15019_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin."},{"key":"15019_CR2","unstructured":"National Cancer Institute. SEER Cancer Stat Facts: Esophageal Cancer. Retrieved 20 January 2021 at https:\/\/seer.cancer.gov\/statfacts\/html\/esoph.html."},{"key":"15019_CR3","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/bjc.2014.579","volume":"112","author":"V Bagnardi","year":"2015","unstructured":"Bagnardi V, Rota M, Botteri E, et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br J Cancer. 2015;112:580\u201393.","journal-title":"Br J Cancer."},{"key":"15019_CR4","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/S1470-2045(21)00279-5","volume":"22","author":"H Rumgay","year":"2021","unstructured":"Rumgay H, Shield K, Charvat H, et al. Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study. Lancet Oncol. 2021;22:1071\u201380.","journal-title":"Lancet Oncol."},{"key":"15019_CR5","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/ijc.2910380313","volume":"38","author":"C La Vecchia","year":"1986","unstructured":"La Vecchia C, Liati P, Decarli A, et al. Tar yields of cigarettes and the risk of oesophageal cancer. Int J Cancer. 1986;38:381\u20135.","journal-title":"Int J Cancer."},{"key":"15019_CR6","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","volume":"33","author":"R Obermannova","year":"2022","unstructured":"Obermannova R, Alsina M, Cervantes A, et al. Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment, and follow-up. Ann Oncol. 2022;33:992\u20131004.","journal-title":"Ann Oncol."},{"key":"15019_CR7","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","volume":"16","author":"J Shapiro","year":"2015","unstructured":"Shapiro J, van Lanschot J, Hulshof M, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090\u20138.","journal-title":"Lancet Oncol."},{"key":"15019_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10388-015-0515-3","volume":"13","author":"Y Tachimori","year":"2016","unstructured":"Tachimori Y, Ozawa S, Numasaki H, et al. Efficacy of lymph node dissection by node zones according to tumor location for esophageal squamous cell carcinoma. Esophagus. 2016;13:1\u20137.","journal-title":"Esophagus."},{"key":"15019_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10388-016-0551-7","volume":"14","author":"Japan Esophageal Society","year":"2017","unstructured":"Japan Esophageal Society. Japanese Classification of Esophageal Cancer, 11th edition: part I. Esophagus. 2017;14:1\u201336.","journal-title":"Esophagus."},{"key":"15019_CR10","doi-asserted-by":"crossref","unstructured":"Ajani JA, D'Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers, Version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17:855\u201383.","DOI":"10.6004\/jnccn.2019.0100"},{"key":"15019_CR11","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1002\/cncr.34176","volume":"128","author":"S Park","year":"2022","unstructured":"Park S, Oh D, Choi YL, et al. Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Cancer. 2022;128:2148\u201358.","journal-title":"Cancer."},{"key":"15019_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00280-005-0038-z","volume":"57","author":"A Faried","year":"2006","unstructured":"Faried A, Faried LS, Kimura H, et al. Differential sensitivity of paclitaxel-induced apoptosis in human esophageal squamous cell carcinoma cell lines. Cancer Chemother Pharmacol. 2006;57:301\u20138.","journal-title":"Cancer Chemother Pharmacol."},{"key":"15019_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semcancer.2005.07.008","volume":"16","author":"TL Whiteside","year":"2006","unstructured":"Whiteside TL. Immune suppression in cancer: effects on immune cells, mechanisms, and future therapeutic intervention. Semin Cancer Biol. 2006;16:3\u201315.","journal-title":"Semin Cancer Biol."},{"key":"15019_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12929-022-00873-4","volume":"29","author":"CH Hsieh","year":"2022","unstructured":"Hsieh CH, Kuan WH, Chang WL, et al. Dysregulation of SOX17\/NRF2 axis confers chemoradiotherapy resistance and emerges as a novel therapeutic target in esophageal squamous cell carcinoma. J Biomed Sci. 2022;29:90.","journal-title":"J Biomed Sci."},{"key":"15019_CR15","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nm0497-451","volume":"3","author":"YJ Guo","year":"1997","unstructured":"Guo YJ, Che XY, Shen F, et al. Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies. Nat Med. 1997;3:451\u20135.","journal-title":"Nat Med."},{"key":"15019_CR16","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1200\/JCO.2018.79.1483","volume":"36","author":"H Yang","year":"2018","unstructured":"Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol. 2018;36:2796\u2013803.","journal-title":"J Clin Oncol."},{"key":"15019_CR17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0022-5223(19)35570-9","volume":"100","author":"S Abe","year":"1990","unstructured":"Abe S, Tachibana M, Shiraishi M, et al. Lymph node metastasis in resectable esophageal cancer. J Thorac Cardiovasc Surg. 1990;100:287\u201391.","journal-title":"J Thorac Cardiovasc Surg."},{"key":"15019_CR18","doi-asserted-by":"crossref","unstructured":"Li K, Leng X, He W, et al. Resected lymph nodes and survival of patients with esophageal squamous cell carcinoma: an observational study.\u00a0Int J Surg. 2023;10.1097.","DOI":"10.1097\/JS9.0000000000000436"},{"key":"15019_CR19","unstructured":"Li K, Nie X, Li C, et al. Mapping of lymph node metastasis and efficacy index in thoracic esophageal squamous cell carcinoma: a large-scale retrospective analysis.\u00a0Ann Surg Oncol. 2023;10.1245."},{"key":"15019_CR20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3892\/ol.2023.13774","volume":"25","author":"K Li","year":"2023","unstructured":"Li K, Du K, Liu K, et al. Impact of two-field or three-field lymphadenectomy on overall survival in middle and lower thoracic esophageal squamous cell carcinoma: a single-center retrospective analysis. Oncol Lett. 2023;25:189.","journal-title":"Oncol Lett."},{"key":"15019_CR21","volume-title":"AJCC Cancer Staging Manual","author":"MB Amin","year":"2016","unstructured":"Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual. 8th edn. New York: Springer; 2016.","edition":"8"},{"key":"15019_CR22","doi-asserted-by":"crossref","unstructured":"Li C, Zhao S, Zheng Y, et al. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (Palace-1). Eur J Cancer. 2021;232\u201341.","DOI":"10.1016\/j.ejca.2020.11.039"},{"key":"15019_CR23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1200\/JCO.2022.40.4_suppl.238","volume":"40","author":"K Kato","year":"2022","unstructured":"Kato K, Ito Y, Daiko I, et al. A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG 1109 NExT study. J Clin Oncol. 2022;40:238.","journal-title":"J Clin Oncol."},{"key":"15019_CR24","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1200\/JCO.21.02500","volume":"24","author":"MA Patel","year":"2022","unstructured":"Patel MA, Kratz JD, Lubner SJ, Loconte NK, Uboha NV. Esophagogastric cancers: integrating immunotherapy therapy into current practice. J Clin Oncol. 2022;24:2751\u201362.","journal-title":"J Clin Oncol."},{"key":"15019_CR25","doi-asserted-by":"crossref","unstructured":"Fujita H, Kakegawa T, Yamana H et al. Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer. Comparison of three-field lymphadenectomy with two-field lymphadenectomy. Ann Surg. 1995;5:654\u201362.","DOI":"10.1097\/00000658-199511000-00008"},{"key":"15019_CR26","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jtho.2020.10.157","volume":"2","author":"B Li","year":"2021","unstructured":"Li B, Zhang Y, Miao L, et al. Esophagectomy with three-field versus two-field lymphadenectomy for middle and lower thoracic esophageal cancer: long-term outcomes of a randomized clinical trial. J Thorac Oncol. 2021;2:310\u20137.","journal-title":"J Thorac Oncol."},{"key":"15019_CR27","doi-asserted-by":"crossref","unstructured":"Li K, Leng XF, Du K, et al. Clinical value and efficacy index of lymphadenectomy for thoracic esophageal squamous cell carcinoma. Dis Esophagus. 2022; 2(Suppl):362.","DOI":"10.1093\/dote\/doac051.362"},{"key":"15019_CR28","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1093\/icvts\/ivt070","volume":"16","author":"H Ma","year":"2013","unstructured":"Ma H, Li Y, Ding Z, Liu X, Xu J, Qin J. The clinical significance of subcarinal lymph node dissection in the radical resection of oesophageal cancer. Interact Cardiovasc Thorac Surg. 2013;16:839\u201343.","journal-title":"Interact Cardiovasc Thorac Surg."},{"key":"15019_CR29","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jtcvs.2022.02.050","volume":"164","author":"L Xu","year":"2022","unstructured":"Xu L, Wei XF, Chen XK, et al. Clinical significance of left tracheobronchial lymph node dissection in thoracic esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2022;164:1210\u20139.","journal-title":"J Thorac Cardiovasc Surg."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15019-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-15019-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15019-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T13:04:53Z","timestamp":1715087093000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-15019-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["15019"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-15019-z","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,19]]},"assertion":[{"value":"6 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}